US · Healthcare · Diagnostics & Research
EPS came in at -0.23 against a street estimate of -0.23 — a beat of 0.0%.
Analysts rate Insight Molecular Diagnostics Inc. a buy (3 buy, 2 hold, 0 sell out of 5) with an average price target of $8.25.
| Fund | Stake |
|---|---|
| BROADWOOD CAPITAL Inc | 38.76% |
| Awm Investment Company Inc | 8.67% |
| Vanguard Capital Management, LLC | 2.25% |
| PURA VIDA INVESTMENTS, LLC | 1.48% |
| Geode Capital Management, LLC | 0.79% |
| FNY Investment Advisers, LLC | 0.56% |
| Jane Street Group LLC | 0.48% |
| BlackRock Inc | 0.46% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Insight Molecular Diagnostics Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.